BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis
Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...
562 Views
BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside
BeiGene is the second biotech company to list in Hong Kong under amended listing rules that allow biotech companies which are yet to see a profit...
543 Views
Last Week in GER Research: Ascletis Pharma, China Tower, Pinduoduo, Beigene and CNFinance
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight our sensitivity analysis for Ascletis...
991 Views
BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term
The US-listed BeiGene (BGNE US) aims to list in Hong Kong by raising USD1 billion via issuing new shares. The company plans to use the majority of...
773 Views
BeiGene IPO Preview: Lucrative Lifesavers
BeiGene (BGNE US) is set to become the first overseas listed biotech firm to seek a secondary listing in Hong Kong, under the city’s newly revamped...
697 Views